Is Buying Biocryst Pharmaceuticals Inc (NASDAQ:BCRX), Having Higher Short Interest a Winning Strategy?

May 17, 2018 - By Alfred Lee

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Logo

Investors sentiment decreased to 1.61 in 2017 Q4. Its down 0.08, from 1.69 in 2017Q3. It worsened, as 16 investors sold BioCryst Pharmaceuticals, Inc. shares while 20 reduced holdings. 22 funds opened positions while 36 raised stakes. 87.26 million shares or 9.34% more from 79.80 million shares in 2017Q3 were reported.
Geode Mgmt Lc holds 819,415 shares. Morgan Stanley reported 0% stake. Janney Montgomery Scott Limited has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 30,735 shares. Eventide Asset Management Limited Liability owns 290,000 shares. Renaissance Techs Ltd Limited Liability Company reported 0% stake. Proshare Advsrs Ltd Liability Co has 67,561 shares for 0% of their portfolio. Legal & General Gp Pcl, a United Kingdom-based fund reported 24,265 shares. Aqr Mngmt Ltd holds 53,140 shares. New York-based Bnp Paribas Arbitrage has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Tower Rech Cap Ltd (Trc) has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Emory University invested in 383,768 shares or 1.62% of the stock. Comerica Bancshares holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 16,959 shares. Jane Street Group Limited Liability stated it has 27,549 shares or 0% of all its holdings. Ameritas Invest Partners reported 6,697 shares. Northern Tru has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

The stock of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) registered an increase of 1.94% in short interest. BCRX’s total short interest was 10.90 million shares in May as published by FINRA. Its up 1.94% from 10.69M shares, reported previously. With 440,800 shares average volume, it will take short sellers 25 days to cover their BCRX’s short positions. The short interest to Biocryst Pharmaceuticals Inc’s float is 15.3%.

The stock decreased 0.33% or $0.02 during the last trading session, reaching $5.96. About 1.15 million shares traded or 41.20% up from the average. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has declined 43.31% since May 17, 2017 and is downtrending. It has underperformed by 54.86% the S&P500.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $588.35 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 4 analysts covering BioCryst (NASDAQ:BCRX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. BioCryst had 5 analyst reports since November 28, 2017 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Wednesday, May 9 with “Buy”. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Buy” rating given on Tuesday, November 28 by JMP Securities. The rating was maintained by H.C. Wainwright on Tuesday, January 23 with “Buy”. The rating was upgraded by RBC Capital Markets on Tuesday, January 2 to “Outperform”.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by:, which released: “BioCryst to Announce First Quarter 2018 Financial Results on May 8” on April 26, 2018.‘s article titled: “New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals …” and published on April 26, 2018 is yet another important article.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.